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ABSTRACT
Estrogen receptor  (ER) is an enhancer activat-
ing transcription factor, a key driver of breast can-
cer and a main target for cancer therapy. ER-
mediated gene regulation requires proper chromatin-
conformation to facilitate interactions between ER-
bound enhancers and their target promoters. A major
determinant of chromatin structure is the CCCTC-
binding factor (CTCF), that dimerizes and together
with cohesin stabilizes chromatin loops and forms
the boundaries of topologically associated domains.
However, whether CTCF-binding elements (CBEs)
are essential for ER-driven cell proliferation is un-
known. To address this question in a global manner,
we implemented a CRISPR-based functional genetic
screen targeting CBEs located in the vicinity of ER-
bound enhancers. We identified four functional CBEs
and demonstrated the role of one of them in inducing
chromatin conformation changes in favor of activa-
tion of PREX1, a key ER target gene in breast can-
cer. Indeed, high PREX1 expression is a bona-fide
marker of ER-dependency in cell lines, and is asso-
ciated with good outcome after anti-hormonal treat-
ment. Altogether, our data show that distinct CTCF-
mediated chromatin structures are required for ER-
driven breast cancer cell proliferation.
INTRODUCTION
Approximately 75% of all human breast tumors expresses
ER, a hormone receptor encoded by the ESR1 gene that
functions as a hormone-regulated transcription factor (1,2).
ER is generally activated upon binding of its endogenous
ligand estradiol (E2), which results in the recruitment of a
large spectrum of coregulators to form an active transcrip-
tion complex and associate to the chromatin via Estrogen
Responsive Elements (EREs) (3). Importantly, ER rarely
binds promoters but regulates gene expression by bind-
ing cis-regulatory enhancer elements, which interact in 3D
genomic space with promoter regions of responsive genes
through chromatin looping (4–6).
ER is considered the main driver in these tumors, and
current treatment of ER-positive breast cancer resolve
around endocrine therapies like tamoxifen, which prevents
cofactor recruitment and transcription complex formation
(7) or fulvestrant that induces receptor degradation (8).
Other treatments are based on inhibiting the synthesis of
estrogen with aromatase inhibitors, which prevents receptor
activation. However, resistance to treatment is common and
∼80% of metastases with acquired resistance to endocrine
therapeutics still express ER (9–11). Multiple drivers of
endocrine therapy resistance have been identified, includ-
ing ESR1 activating point mutants (12), ER phosphoryla-
tion (13), overexpression of coregulators (14) and epigenetic
reprogramming of the ER cistrome (15,16). Nonetheless,
other mechanisms of endocrine therapy resistance in breast
cancer are likely to exist.
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Eukaryotic gene expression is tightly controlled by a set
of steps that guarantee precise spatial and temporal gene
expression patterns (17). The regulation of initiation of
transcription by regulatory DNA elements is one of the
most important events in gene expression (18). Regulatory
DNA elements can be classified into two main branches
according to their mode of activity as trans-acting factors
and cis-regulatory elements (19). Cis-regulatory elements
include promoters (20), enhancers (21), silencers (22) and
insulators (23). They coordinate the timing and strength
of gene expression during development and differentiation
(24), growth and stress conditions. While promoters are lo-
cated immediately upstream of their target genes, enhancers
can be located far away from their target promoters on the
linear chromosome template and rely on chromatin struc-
ture (DNA looping) to activate gene expression (25).
One of the most critical determinants of chromatin
structure is the zinc-finger DNA binding protein CTCF
(CCCTC-binding factor) (26,27). Together with cohesin
(28), CTCF functions to insulate enhancers and facilitate
correct enhancer/target-promoter interactions by creating
chromatin territories dubbed as topologically active do-
mains (TADs) (29,30). Two convergent linear CTCF sites
(31) are held together by a cohesin ring and form ‘in-
sulated neighborhoods’ (27) (chromatin loop structures)
which come together to form megabase-scale TADs (32).
Therefore, it is likely that genetic or epigenetic perturbations
of CTCF binding elements (CBEs) may affect chromatin
structure leading to local rewiring of promoter-enhancer
contacts which potentially can change gene expression pat-
terns (27,33,34) and as a result cause a phenotypic changes
in cell behavior (35,36). Indeed, indications for a link be-
tween CTCF and ER-mediated gene expression and phe-
notypic changes were recently made (15,37). By an integra-
tive genomics approach, Chan and colleagues have parti-
tioned the genome to CTCF blocks (genomic regions be-
tween two CBEs), and demonstrated that genes located
within ER-containing CTCF blocks are generally upreg-
ulated in response to estrogen while genes in blocks de-
void of ER not. In fact, the presence of an ER bind-
ing site (EBS) within a CTCF block, and the distance to
the nearest ER, were shown to be the best predictive score
for estrogen-responsive genes (37). Moreover, CTCF bind-
ing appeared not to only mark boundaries for accessibil-
ity and insulated transcriptional blocks, but also seemed
to be required to shape ER-mediated gene expression in
breast cancer cells (15). However, the functional signifi-
cance and the causal role of CTCF binding and associated
gene expression changes to cancer progression are yet to
be explored. Since CBEs and EBSs overlap in thousands
of cases (15) and enhancer/target-gene interactions depend
on proper chromatin interactions, we hypothesize here that
CBEs can affect ER function and induce tumor cell pro-
liferation and resistance to anti-hormonal treatments.
The CRISPR-Cas9 system has been recently harnessed
to delineate regulatory gene expression mechanisms medi-
ated through promoter (38,39) and enhancer regions (40).
Though applied to specific CTCF loci of interest before
(27,34), a genome-wide CRISPR-Cas9 screen systemati-
cally targeting CTCF sites was not yet implemented. In
this study, we designed a customized CRISPR-Cas9 library
to target individual CBEs that reside in close proximity to
EBSs and performed a drop-out genetic screen to iden-
tify CBEs essential for ER-driven cell proliferation. Al-
together, we validated four key CBEs, of which we fur-
ther functionally characterized the one residing in the vicin-
ity of PREX1 (Phosphatidylinositol 3,4,5-trisphosphate-
dependent Rac exchanger 1) promoter; a key driver of
breast cancer cell proliferation.
MATERIALS AND METHODS
Cell lines and chemical reagents
HEK293-T, MDA-MB-231 and MCF-7 cells were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
medium (Gibco), supplemented with 10% Fetal Calf
Serum (Hyclone) and 1% penicillin/streptomycin (Gibco).
For the estrogen-stimulation experiments,MCF-7 cells were
washed three times with phosphate-buffered saline and cul-
tured in phenol red–free DMEM medium (Gibco) supple-
mented with 5% charcoal stripped serum (Gibco) for 72 h
prior to E2 treatment (10−8 M). E2 (17-estradiol) was
purchased from Sigma. All cell lines were obtained from
ATCC.
Custom single guide RNAs (sgRNAs) designed for this study:
Name Oligo1 Oligo2
CTCF ERa MCF7 s
gRNA680
CACCGTGGGCAT
AAGGAGTAACAGA
AAACTCTGTTACTCCT
TATGCCCAC
CTCF ERa MCF7 s
gRNA1117
CACCGCAATGCC
AGGCTCTGCCATC
AAACGATGGCAGAG
CCTGGCATTGC
CTCF ERa MCF7 s
gRNA1118
CACCGTTCGCGC
TGCTGCTGCCAGA
AAACTCTGGCAGCA
GCAGCGCGAAC
CTCF ERa MCF7 s
gRNA1659
CACCGAGACAGC
GGTACCTGTCAGG
AAACCCTGACAGGT
ACCGCTGTCTC
CTCF ERa MCF7 s
gRNA1661
CACCGAAAGACA
GCGGTACCTGTCA
AAACTGACAGGTAC
CGCTGTCTTTC
CTCF ERa MCF7 s
gRNA810
CACCGGACGCTT
GGCTGCCACCTGG
AAACCCAGGTGGCA
GCCAAGCGTCC
CTCF ERa MCF7 s
gRNA811
CACCGGAGGACG
CTTGGCTGCCACC
AAACGGTGGCAGCC
AAGCGTCCTCC
CBE2 #1 CACCGGCTCGAG
CATTGGTGCTCTC
AAACGAGAGCACCA
ATGCTCGAGCC
CBE2 #2 CACCGCGAGCAT
TGGTGCTCTCTGG
AAACCCAGAGAGCA
CCAATGCTCGC
EBE24365 #1 CACCGAGGAGCA
GGCTGACCTGACC
AAACGGTCAGGTCA
GCCTGCTCCTC
EBE24365 #2 CACCGGTGACTC
TGTTCTCCTGGTC
AAACGACCAGGAGA
ACAGAGTCACC
intron #1 CACCGGATGGTG
TCTGCGAACAGCG
AAACCGCTGTTCGC
AGACACCATCC
intron #2 CACCGATTTTAG
GGTTGTCCCCACG
AAACCGTGGGGACA
ACCCTAAAATC
PREX1 exon #1 CACCGGCGCGGC
CGCGCTAGAATGG
AAACCCATTCTAGC
GCGGCCGCGCC
PREX1 exon #2 CACCGTGGGCGC
CTCCATTCTAGCG
AAACCGCTAGAATG
GAGGCGCCCAC
PREX1 exon #3 CACCGGCAGAAC
GTGGCCGACTCAG
AAACCTGAGTCGGC
CACGTTCTGCC
PREX1 exon #4 CACCGGCATCGC
ATCCGGCAGAACG
AAACCGTTCTGCCG
GATGCGATGCC
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Pooled library cloning
Standard de-salted DNA oligonucleotides were synthesized
and purchased from IDT (Integrated DNA Technologies)
to construct sgRNA library for CTCF sites in the vicinity of
ER (1709 sgRNAs+82 control sgRNAs). Complementary
single-stranded oligos were phosphorylated and annealed
by combining 100 M oligos, 1× T4 PNK Buffer, 1 mM
adenosine triphosphate (ATP), 5U T4 PNK and incubat-
ing the reaction at 37◦C/30 min, 95◦C/5 min followed by
ramp down to 25◦C at 5◦C/min. Annealed oligos were di-
luted at 1:1000 in sterile water, and ligated to plasmid vec-
tor lentiCRISPR v2 (gift from Feng Zhang (Addgene plas-
mid #52961)) using the following parameters: 50 ng BsmBI
(Fermentas) digested plasmid, 1l diluted oligo duplex, 1×
Ligation Buffer (Roche), 5U T4 DNA Ligase (Roche) incu-
bated at RT/30 min. We did five independent ligation reac-
tions per pool and used them to transformhighly competent
Escherichia coli cells (EletroSHOX - Bioline, BIO-85038)
according to manufacturer’s protocol. In order to assess the
complexity of our libraries, we plated 1 l of cell transfor-
mation mixture on LB agar plates containing Ampicillin,
incubated them overnight at 37◦C, and counted individual
bacterial colonies after 16 h. At this point, we estimated
that each individual sgRNA is covered >100×, ensuring
that our libraries have high-complexity and are suitable for
pooled screening. Transformationmixtures were combined,
grew in liquid LB until OD600= 0.8 was reached, and plas-
mid DNAwas harvested using Genopure PlasmidMaxi kit
(Roche).
Lentivirus production and purification
To produce lentivirus, 4× 106 HEK293T cells per pool were
seeded in five 100 mm dishes one day prior to transfection.
For each dish, we diluted 10g of CRISPR-CTCFER plas-
mid library, 3.5 g of pVSV-G, 5 g of pMDL RRE and
2.5 g of pRSV-REV in 450 l of 0.1× TE/H2O, added 50
l of CaCl2 and incubated 5 min at RT. Plasmid DNA was
precipitated by adding 500l 2×HEPES-buffered saline to
the solution while vortexing at full-speed. The precipitate
was added immediately to the plate and the cells were in-
cubated for 14 h at 37◦C, after which the medium was re-
freshed. Lentivirus-containing supernatants were collected
60 h post-transfection, filtered through a 0.45 m mem-
brane (Milipore Steriflip HV/PVDF) and stored at −80◦C.
All cell types and lentivirus batches tested were titrated in
order to achieve a MOI of 0.4–0.5. Cell lines were infected
with lentivirus supernatants supplemented with 8 g/ml
polybrene (Sigma). At 24 h post-infection, medium was
replaced and cells were selected with 2 g/ml puromycin
(Gibco). Antibiotic selection was stopped as soon as no sur-
viving cells remained in the no-transduction control plate.
All experiments were performed within the first 15 days fol-
lowing the antibiotic selection.
CRISPR-Cas9 dropout screen in breast cancer cells
MCF-7 and MDA-MB-231 cells were infected with three
independent pools of CRISPR-CTCFER. We infected
∼45 000 cells per vector, to ensure that every sgRNA was
present in the cell population at the start of the experiment.
Following antibiotic selection, cells were allowed to prolif-
erate for 48 h to clear potentially toxic sgRNAs from the
population. At this time point, we harvested half of the cells
infected with CRISPR-CTCFER pools (T = 0). The re-
maining cells were placed in culture, allowed to proliferate
for 20 days, and then harvested (T = 20). Cell pellets were
stored at −80◦C and processed later on for further analy-
sis. Genomic DNAwas isolated from the harvested library-
transduced cells, and amplified for the integrated vectors by
polymerase chain reaction (PCR), and sequenced by Next-
generation sequencing (NGS) to quantify the abundance
of integrated sgRNAs present in each population. Read
counts in each sample were normalized to 1M reads (RPM)
and enrichment (depletion) scores were calculated for each
sgRNA vector, in each cell line (MCF-7 and MDA-MB-
231) by comparing its normalized frequency at T = 20 and
T = 0 pools. (Only sgRNAs covered by at least 50 reads
were considered. To avoid inflation of FC for sgRNAs cov-
ered by low number of reads, RPMs below 5 were set to
5). These enrichment/depletion scores were then standard-
ized to Z-scores (raw counts, RPM, enrichment scores and
Z-scores are provided in Supplementary Table S1). These
standardized enrichment scores showed high correlation be-
tween replicates from the same cell line (SupplementaryFig-
ure S1A) Difference between the mean standardized en-
richment scores in MCF-7 and MDA-MB-231 cells (which
serve as control in the screen as they are not dependent on
ER) were calculated for each sgRNA. For validation, we
selected sgRNA vectors whose repressive effect on prolifer-
ation was at least 30% stronger inMCF-7 cells compared to
MDA-MB-231 cells.
Genomic DNA sequencing to identify sgRNAs
Frozen cell pellets were thawed and genomic DNA (gDNA)
was isolated with DNeasy Blood and Tissue kit (Qiagen).
Identification of sgRNAs was done by PCR in two steps.
For the first PCR, the amount of input gDNA was calcu-
lated to achieve∼500 coverage (assuming that 106 cells con-
tain 6.6 g gDNA), which resulted in 5 g for CRISPR-
CTCFER. For each sample, we performed two separate
reactions (max. 1 g gDNA per reaction) using Phusion
DNA polymerase (Thermo Scientific) and combined the re-
sulting amplicons. In the first PCR, we used the following
primer sequences to amplify sgRNAs:
PCR1 F1
ACACTCTTTCCCTACACGACGCTCTTCCGATC
TXXXXXXGGCTTTATATATCTTGTGGAAAGGA
CG (XXXXXX represents a 6 bp barcode)
PCR1 R1
GTGACTGGAGTTCAGACGTGTGCTCTTCCGAT
CTACTGACGGGCACCGGAGCCAATTCC
A second PCR was performed to attach Illumina adap-
tors and index samples. The second PCR was done in 50 l
reaction volume, including 7 l of the product from the first
PCR and using the following primers:
PCR2 P5
AATGATACGGCGACCACCGAGATCTACACTCT
TTCCCTACACGACGCTCTTCCGATCT
PCR2 P7
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CAAGCAGAAGACGGCATACGAGATXXXXXX
GTGACTGGAGTTCAGACGTGTGCTCTTCCGAT
CT (XXXXXX represents a 6 bp index)
Amplification was carried out with 15 cycles for both
first and second PCR. After the second PCR, resulting am-
plicons were purified using Agencourt AMPure XP beads
(Beckman Coulter), quantified in a Bioanalyzer 2100 (Agi-
lent), mixed and sequenced in a HiSeq 2500 (Illumina).
Genomic DNA sequencing to identify CRISPR-induced mu-
tations
Cell pellets were collected and gDNA was isolated with
DNeasy Blood and Tissue kit (Qiagen). Amplification of
target regions for sequencing was done by PCR in two
steps. For each sample, we used 500 ng of gDNA as input
for the first PCR (done in duplicate). Resulting amplicons
were combined and we used 10 l as input for the second
PCR. Amplification was carried out with 20 cycles for both
first and second PCR. After the second PCR, amplicons
were purified using Agencourt AMPure XP beads (Beck-
man Coulter), quantified in a Bioanalyzer 2100 (Agilent),
mixed and sequenced in a HiSeq 2500 (Illumina).
List of PCR primers:
Name Primers
sgRNA680 F CTTGACTGGCACCTGGAGAG
sgRNA680 R ATTCCATGGTGTCTGCTGGG
sgRNA680 P5 SeqF ACACTCTTTCCCTACACGACGCTC
TTCCGATCT CGTGAT
AGAGACCATGTTGTGCCAGG
sgRNA680 P7 SeqR GTGACTGGAGTTCAGACGTGTG
CTCTTCCGATCTGTTTTGTGTGGG
GGCCTACT
sgRNA1118 F GTGAGAGGGTGAGAGTGTGC
sgRNA1118 R CTGGGGAGTTCTGGCTCTTG
sgRNA1118 P5 SeqF ACACTCTTTCCCTACACGACGCTC
TTCCGATCT ACATCG
CATGCACACACACACACACA
sgRNA1118 P7 SeqR GTGACTGGAGTTCAGACGTGTG
CTCTTCCGATCTAGCTCAGTCATG
TCAGCCAC
sgRNA1659 F CACCAGGCTTGAGAGAAGCA
sgRNA1659 R CATAGCCCTGTACCTCTGCG
sgRNA1659 P5 SeqF ACACTCTTTCCCTACACGACGCTC
TTCCGATCT GCCTAA
TAGGTTATCTGCTGGGCCCA
sgRNA1659 P7 SeqR GTGACTGGAGTTCAGACGTGTG
CTCTTCCGATCTGGGAATCGAGGC
TCCCTAAG
sgRNA1661 P5 SeqF ACACTCTTTCCCTACACGACGCTC
TTCCGATCT TGGTCA
TAGGTTATCTGCTGGGCCCA
sgRNA810 F GTTGGAACTGGGAGGAGCTC
sgRNA810 R GACTGGCTTCAGCATTGTGC
sgRNA810 P5 SeqF ACACTCTTTCCCTACACGACGCTC
TTCCGATCT CACTGT
CAACCCGTTTTGGAAGCCAG
sgRNA810 P7 SeqR GTGACTGGAGTTCAGACGTGTG
CTCTTCCGATCTGAGTGTGGCG
AGCTGGATC
sgRNA811 P5 SeqF ACACTCTTTCCCTACACGACGCTC
TTCCGATCT ATTGGC
CAACCCGTTTTGGAAGCCAG
Competitive proliferation assay
MCF-7 and MDA-MB-231 cells were infected with in-
dicated sgRNAs to validate the results of the CRISPR-
CTCFER screen. Separately, we generated polyclonal
MCF-7 and MDA-MB-231 cells stably expressing GFP us-
ing pLKO.1-GFP vector. GFP expressing cells were mixed
in a 1:3 ratio with cells containing individual sgRNAs. The
percentage of GFP expressing cells was assessed by flow cy-
tometry at the beginning of the experiment (T = 0) and ev-
ery 72 h onward (T = 3 days and T = 6 days). For every
condition, 10 000 events were recorded and the data was
analyzed using FlowJo software.
RNA isolation, reverse-transcription and quantitative real-
time PCR (qPCR)
After the antibiotic selection was completed, cells were kept
in cell culture at least 2–3 days in order to eliminate the ad-
verse effect of antibiotic on cells. Total RNA was extracted
using TRIsure (Bioline) reagent and following the manu-
facturers protocol. cDNA was produced with either Su-
perScript III (Invitrogen) or High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystem) using 2–4 g of to-
tal RNA per reaction. qPCR reaction was performed with
SYBR green I Master mix in a LightCycler 480 (Roche).
TATA-binding protein (TBP) was used as an internal con-
trol.
List of qPCR primers:
Forward Reverse
PREX 1 TGGGACTCAT
CCCTGAACTC
CTGTGCAACAAT
GGCTTCAT
TBP GGAGAGTTCT
GGGATTGTAC
CTTATCCTCATGAT
TACCGCAG
Western blot analysis
Whole-cell lysates were prepared as previously described
(41). Membranes were immunoblotted with the following
antibodies: PREX1 (ab183643, Abcam; 1:500), and beta-
Actin (A2228, Sigma; 1:5000). Protein bands were visual-
ized using corresponding secondary antibodies (Dako) and
ECL reagent (GE Healthcare).
GRO-seq
GRO-seq was performed as described before with minor
modifications. Briefly, 5 × 106 nuclei were isolated and in-
cubated 5 min at 30◦C with equal volume of reaction buffer
(10 mM Tris–Cl pH 8.0, 5 mM MgCl2, 1 mM DTT, 300
mMKCL, 20 units of SUPERase In, 1% sarkosyl, 500 M
ATP, GTP and Br-UTP, 0.2 M CTP+32P CTP) for the
nuclear run-on. The reaction was stopped and total RNA
was extracted with Trizol LS (Invitrogen) according to
the manufacturer’s instructions. RNA was fragmented us-
ing fragmentation reagents (Ambion) and the reaction was
purified through p-30 RNAse-free spin column (BioRad).
BrU-labeled RNA was immunoprecipitated with anti-BrU
agarose beads (Santa Cruz), washed one time in binding
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buffer, one time in low salt buffer (0.2× SSPE, 1 mM
ethylenediaminetetraacetic acid (EDTA), 0.05%Tween-20),
one-time high salt buffer (0.25× SSPE, 1mMEDTA, 0.05%
Tween-20, 137.5 mM NaCl) and two times in TET buffer
(TE with 0.05% Tween-20). RNA was eluted with elution
buffer (20 mMDTT, 300 mMNaCl, 5 mM Tris–Cl pH 7.5,
1 mM EDTA and 0.1% sodium dodecyl sulphate) and iso-
lated with Trizol LS. After the binding step, BrU-labbeled
RNAwas treatedwith tobacco acid pyrophosphatase (TAP,
Epicenter) to remove 5′-methyl guanosine cap, followed
by T4 polynucleotide kinase (PNK; NEB) to remove 3′-
phosphate group. BrU-containing RNA was treated with
T4 PNK again at high pH in the presence of ATP to add
5′-phosphate group. The reaction was stopped and RNA
was extracted with Trizol LS. Sequencing libraries were pre-
pared using TruSeq Small RNA kit (Illumina) following
manufacturer’s instructions. Briefly, end-repaired RNAwas
ligated toRNA3′ and 5′ adapters, followed byRT-PCRam-
plification. cDNA was purified using Agencourt AMPure
XP (Beckman Coulter) and amplified by PCR for 12 cy-
cles. Finally, amplicons were cleaned and size-selected us-
ing Agencourt AMPure XP (Beckman Coulter), quantified
in a Bioanalyzer 2100 (Agilent), and sequenced in a HiSeq
2500 (Illumina). Sequenced reads were aligned to the hu-
man genome (hg19) using bowtie2. Statistics on the number
of sequenced and mapped reads is given in Supplementary
Table S3.
RNA-seq
After the antibiotic selection was completed, cells were kept
in cell culture until they reach 70–80% confluency. Total
RNA was extracted using TRIsure (Bioline) reagent and
following the manufacturers protocol. RNA-seq samples
were processed with TruSeq RNA library prep kit v2 (Il-
lumina) and sequenced in a HiSeq 2500 (Illumina). Se-
quenced reads were aligned to the human genome (hg19)
using TopHat2 (42) and gene expression counts were cal-
culated using HTseq (43) based on Ensembl’s human gene
annotations (v69) (44). Expression levels were normalized
using quantile normalization. Statistics on the number of
sequenced andmapped reads is given in Supplementary Ta-
ble S3.
Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitations were performed as pre-
viously described (16,45). Cells were fixed with formalde-
hyde (1%) for 10 min and subsequently quenched with
glycine. Following that, samples were lysed as described
(46) and sonicated for at least 11 cycles of 30 s on, 30 s
off using a Diagenode Bioruptor Pico. We used antibod-
ies against ER (MS-315-P, Thermo Scientific), FOXA1
(ab5089, Abcam) and CTCF (07–729, Merck Millipore).
For ER/FOXA1 ChIPs, 5 g of antibody was conju-
gated with 50 l Protein G magnetic beads. On the other
hand, for CTCF ChIP 7.5 l of the antibody was conju-
gated with 50 l Protein Amagnetic beads. Immunoprecip-
itated DNA was processed for library preparation by us-
ing TruSeq ChIP Library Preparation Kit. Samples were
sequenced using an Illumina Hiseq2500 genome analyzer
(65 bp reads, single end), and aligned to the Human Ref-
erence Genome (hg19, February 2009). Reads were filtered
based onMAPQ quality (quality ≥ 20) and duplicate reads
weremarked. Peak calling over input control was performed
using DFilter (47) and MACS 1.4 (48) peak callers. MACS
was run with the following parameters: bw 300 -m 10,30 -p
1.00e-7 –nomodel. DFilter was run with bs = 50, ks =
30, refine, nonzero. The peaks shared by both peak callers
were used for analysis. For pair-wise comparison of ChIP-
seq, the binding signals in the union of the binding sites
from the data pair were quantified using count per mil-
lion reads using pybedtools (49,50). The binding profiles are
compared and visualized using seaborn v0.7.0 (51) where
the sites overlap with the target of sgRNAs are highlighted
in the scatter plot.
4C
4C-seq was performed as described previously (52). Briefly,
after obtaining a single cell suspension, crosslinking of the
nuclei, chromatinwas digestedwithMboI and subsequently
re-ligated. Proteinase K was used to de-crosslink the DNA
o/n at 65◦C. DNA was isolated by phenol/chloroform ex-
traction and subsequently digested with a Csp6I. To cre-
ate circular DNAmolecules, digested DNA was ligated un-
der diluted conditions (7 ml). DNA was precipitated with
1/10 volume 3M sodium acetate and 1 volume isopropanol.
DNA was quantified using Qbit (Thermo Fisher). 4C PCR
was done using Expand long template polymerase (Sigma-
Aldrich) in five separate PCR reactions using 100 ng per
PCR.
After Illumina sequencing, reads were demultiplexed
based on the primer sequence of the viewpoint (first 20 nt
of the sequence read). Trimmed reads we mapped to the
human genome (hg19) with BWA-MEM (53). Only reads
whose start overlapped with an MboI restriction site were
retained for further analysis. Read count files were normal-
ized using peakC (54) before further analysis. CTCF motif
positions are based on a previously done ChIPseq (15).
PREX1 expression data and patient survival
The performance of the PREX1 classifier for clinical out-
come was assessed using the METABRIC patient series
(55). Survival curves for PREX1 expression (lowest versus
highest quartile) were constructed using the Kaplan–Meier
method and compared using log-rank test. Adjusted Cox
proportional hazard regression analyses were performed
with the following covariates: PREX1 expression, age, tu-
mor grade (grade 1 versus grade 2 versus grade 3), tumor
size, tumor stage (1 versus 2 versus 3 versus 4 versus 5) and
lymph node status (negative versus positive). When com-
paring the performance of the PREX1 classifier in the hor-
monal treatment setting, the group of patients receiving
hormonal treatment was down sampled to match the pa-
tient numbers of the other group. Pearson’s correlation co-
efficient was used to assess the correlation between PREX1
and ESR1 expression. A P-value < 0.05 was considered as
a significant result.
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Analysis of PREX1 expression and ESR1 KD sensitivity in
breast cancer cell
We compared the expression levels of PREX1 (as measured
byRNA-seq across the breast cancer cell lines of the Cancer
Cell Line Encyclopedia) with theAtaris andDemeter scores
for ESR1 knockdown previously reported by the projects
DRIVE (56) and Achilles (57), respectively. The sensitivity
scores of ESR1 knockdown correspond to an aggregate of
17 and 10 shRNAs for DRIVE and Achilles, respectively.
Analysis of PREX1 and ESR1 expression in tumor samples
The expression levels of PREX1 and ESR1 (log2 RNA-seq)
were analyzed in 1095 breast cancer samples. The data was
obtained from TCGA.
RESULTS
A functional genetic screen identifies CBEs essential for
ER-mediated mitogenic signaling
We hypothesized that correct chromatin structure is re-
quired to facilitate ER-driven breast cell proliferation.
As CTCF is one of the major determinants of chromatin
structure, we setup a functional genetic screen in breast
cancer cell lines to uncover CTCF-mediated DNA loops
whose knockout attenuates ER-mediated cell prolifera-
tion. We first constructed a CRISPR-Cas9 single guide
RNA (sgRNA) library to target CBEs that are both en-
gaged in DNA loop formation (anchor CTCF sites) and lo-
cated in the vicinity of ER-bound enhancers (Figure 1A).
Initially, anchor CBEs were bioinformatically mapped us-
ing ENCODE’s Chromatin Interaction Analysis by Paired-
End Tag Sequencing (ChIA-PET) data in MCF-7 cells (4).
Then, we searched for evidence of direct CTCF-binding by
crossing this result with ENCODE CTCF ChIP-seq data
in MCF-7 and the presence of a CTCF-motif in each re-
gion (CTCF motif was derived by MEME and then used
by FIMO (using cutoff of P < 10–5) to scan the peaks
for its hits). This set of CTCF anchor sites was intersected
with a map of ER-bound active enhancers (identified by
the overlap of ER binding sites (5) and ENCODE p300
peaks in MCF-7) to select those that reside within a 100
Kb distance from any ER-bound enhancer. This pipeline
resulted in 668 CBEs to which we generated 1,709 target-
ing sgRNAvectors.We also added 82 non-targeting sgRNA
vectors (negative controls) and an sgRNA vector targeting
ER-bound enhancer (ER1830) that we previously showed
its requirement for mediating ER-driven cell proliferation
(positive control (40,58)). A lentiviral library was generated
and named as CRISPR-CTCFER.
Next, we transduced MCF-7 (ER-positive) and MDA-
MB-231 (ER-negative) breast cancer cell lines with the
CRISPR-CTCFER library (three biological replicates, 0.3
MOI, 500× coverage). Depletion scores were calculated for
each sgRNA vector in each cell line (MCF-7 and MDA-
MB-231) by comparing its normalized abundance in the
T = 20 and T = 0 pools. These scores showed high cor-
relation between the biological replicates of the same cell
line (Figure 1B, Supplementary Figure S1A and Table S1
and 4). We aimed to find sgRNAs whose abundance was
reduced specially in MCF-7 without observing any signifi-
cant change in MDA-MB-231 cells. As expected, none of
the negative controls showed any significant reduction in
abundance (Supplementary Figure S1B), while the abun-
dance of sgRNA-ER1830 was highly reduced only inMCF-
7 cells (Figure 1C). Importantly, this experiment identified
four CBEs (three of which were targeted by two indepen-
dent sgRNAs) with a marked negative effect on the prolif-
eration of MCF-7 but no significant effect on MDA-MB-
231 cells (Figure 1C and Supplementary Figure S1B). Sin-
gle transductions of these hits confirmed the functionality
of the four CBEs by growth competition assays (Figure 1D;
Supplementary Figure S2A and B). Following 9 days of cul-
turing, each of the identified sgRNAs attenuated cell prolif-
eration to a similar extent as observed with the positive con-
trol sgRNA-ER1830 (40,58). Thus, our functional genetic
screen approach has yielded fourCBEs that affect the prolif-
eration of MCF-7 while having no effect on MDA-MB-231
cells.
Interestingly, examination of a publicly available dataset
that profiled transcriptional responses to estradiol treat-
ment in MCF-7 cells (using the GRO-seq technique) (59),
showed that for all the four validatedCBEs, the nearest gene
was markedly responsive (induction above 2-fold) to the
treatment (P = 0.0003; binomial test using the overall pro-
portion of genes that were induced more than 2-fold in the
dataset): ESRP2, AKAP1, BICD2 and PREX1 located, re-
spectively, 7k, 35k, 48k and 36k bps from the CBEs targeted
by sgRNA680, sgRNA810, sgRNA1659 and sgRNA1118
(Supplementary Table S2).
CBEs are required for local gene expression
We studied in a greater detail the impact of a subset of the
validated sgRNAs (one from each of the four CBEs de-
tected by the screen) on genome integrity and gene expres-
sion. First, we interrogated the level of DNA editing at the
target sites by next-generation sequencing and found the
expected >50% mutant allele frequencies, the majority of
DNA alterations occurring within 15 nt from the planned
cleavage sites (Figure 1E, left panel and Supplementary Fig-
ure S4A and B). Second, using mRNA sequencing, we as-
sessed changes in gene expression between our hits and a
non-targeting sgRNA.Notably, in all cases, this analysis de-
tected a mild (∼10–50% reduction) but consistent negative
impact on the expression of a handful of genes in the vicin-
ity of the targeted regions (Figure 1E, right panel and Sup-
plementary Figure S2C). Moreover, we used two publicly
available GRO-seq datasets that profiled transcriptional re-
sponses to E2 in MCF-7 cells to examine the response of
genes in the vicinity of the four validated CBEs (±400 kbp;
Figure 1E) to estrogen (5,59). In both cases, nearby genes
showed significant induction upon E2 treatment (Supple-
mentary Figure S2D), suggesting that the selected CBEs are
required for optimal local gene expression (27).
A key role for CBEs in controlling ER-mediated PREX1
transcript activation
Next, we focused on the CBE region targeted by
sgRNA1117 and sgRNA1118 (named as CBE1). This
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Intersection with CTCF peaks (ChIP-Seq) (20.568)
Presence of CTCF motif (9.615)
ERα-p300 overlapped sites (ChIP-Seq) (1.228)
Loop A Loop B
CTCF p300ERα
0-100 kb CTCF sites within 0-100 kb distance (668)
Generate sgRNA (1-3 per each site)
TOTAL: 1.709 sgRNAs (+ 82 control sgRNAs)
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Figure 1. A focused CRISPR-Cas9 genetic screen identifies CBEs required for mitogenic function of ER. (A) The selection criteria and a summary of the
pipeline used to generate a customized CRISPR-Cas9-based library (named as CRISPR-CTCFER). The number in brackets indicates remaining CTCF
binding sites. (B) Screening strategy based on negative selection of sgRNAs. (C) Distribution of sgRNAs’ standardized enrichment scores (Z-scores) in
onlyMCF-7 (left) and inMCF-7 relative toMDA-MB-231 cells (right). A green dot represents the positive control sgRNA targeting enhancer1830 (labeled
as enh1830) (40). (D) Validation of candidate hits by a competitive proliferation assay in MCF-7 and MDA-MB-231 cells. CNT indicates a non-targeting
sgRNA. sgRNA targeting enhancer1830 was used as a positive control (40). GFP positive cells were determined by flow cytometry. For complete plots see
Figure S1A. (E) RNA-seq showed a local downregulation of the genes residing within 400 kbps away from each target site. CNT indicates a nontargeting
sgRNA. Heatmap represents Z-score of expression fold-change (between the test and control sgRNAs). Mutation profile of each CBE target site was
determined by DNA-seq experiment, and is presented at the left-hand side. In all samples the frequency of CRIPSR-Cas9 meditated mutations at the
target CBE was more than 50%.
CBE has a strong effect on PREX1 expression, a target
gene that shows a robust transcriptional activation follow-
ing estradiol treatment in MCF-7 cells (∼2-fold, Figure
2E). Expression analysis of all genes residing within a 2MB
window around the target site (CBE1) indicated a signifi-
cant effect on the mRNA level of PREX1 (Figures 1E and
2A). PREX1 is a Rac guanine nucleotide exchange factor,
whose activity promotes breast cancer cell proliferation
through the activation of the extracellular signal-regulated
kinases (ERK1/2) (60). The PREX1 locus is frequently
amplified in various cancer types (61,62), especially in
breast cancer tumors (up to 30%) with a preference for
ER-positive cases (63), suggesting an oncogenic potential
within the ER pathway. Using qRT-PCR, we validated
the changes in PREX1 gene expression induced by both
CBE1 sgRNAs (Figure 2B). Notably, CRISPR-mediated
targeting of PREX1 exons (Figure 2D and Supplementary
Figure S2E), but not introns (Figure 2C and Supplemen-
tary Figure S4D), resembled the effect of targeting CBE1
in MCF-7 cells (Figure 2D). Intriguingly, in the same
sgRNA1117 or sgRNA1118-transduced MCF-7 cell popu-
lations, we observed marked reduction in the protein levels
of PREX1 isoforms (Supplementary Figure S3). It should
be noted that due to the amplification of PREX1 locus in
MCF-7 cells, a subtle effect of CRISPR-Cas9 targeting
was observed when introns were targeted (64). In contrast
to the effect in MCF-7 cells, targeting PREX1 exons did
not affect the proliferation capacity of MDA-MB-231
cells (Figure 2D)––though PREX1 locus is amplified in
MDA-MB-231 too.
To examine the estradiol (E2) responsiveness, we cultured
MCF-7 cells (wildtype and CBE1 knockout) in hormone-
deprived medium and subsequently treated with E2 or
DMSO control for 30 min, 60 min and 6 h and measured
PREX1mRNA expression. Indeed,PREX1 expression was
significantly increased after E2 treatment (Figure 2E and
Supplementary Figure S2F), indicating that PREX1 is a
primary target gene of ER. Furthermore, knocking out
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Figure 2. A key role for CBE1 in ER-mediated stimulation of PREX1 activity. (A) Gene expression fold-change (log2) between sgRNA1118 (targeting
CBE1) and non-targeting control depicted for genes in chr20 (the location of sg1118 CRISPR-Cas9 cut site is set to 0). The red line is a lowess (lo-
cally weighted scatterplot smoothing) regression curve fitted to the data. (B and C) Relative expression levels of PREX1 was measured by qRT-PCR in
sgRNA1117 and sgRNA1118 (targeting CBE1) and intron targeted MCF-7 cells, compared with control non-targeting sgRNA (CNT). Gene expression
levels were normalized to TBP. n = 3 ***P< 0.005, *P< 0.05, two-tailed Student’s t-test. (D) Competitive proliferation assays in MCF-7 and MDA-MB-
231 after transduction with individual sgRNAs targeting PREX1 gene. Values on day 6 (T = 6) and day 9 (T = 9) were normalized to day 0 (T = 0). ***P
< 0.005, **P < 0.01, *P < 0.05, two-tailed Student’s t-test. n.s., not significant.
CBE1 significantly compromised the induction of PREX1
expression by E2 (Figure 2E and Supplementary Figure
S2F). Moreover, examining genes in the vicinity of PREX1
gene indicated that regardless of their induction by E2,
CBE1 compromised their expression, substantiating its im-
pact on local gene expression (Supplementary Figure S2G).
Altogether, our experiments revealed a key role for CBE1 in
ER-mediated stimulation of PREX1 levels.
An interplay between several CBEs regulate PREX1 expres-
sion
To further assess the binding of CTCF to CBE1 upon
sgRNA introduction, we performed CTCF chromatin-
immunoprecipitation and sequencing (ChIP-seq) experi-
ments. This analysis revealed a moderate binding of CTCF
to CBE1, which was significantly reduced in cells trans-
ducedwith either sgRNA1117 or 1118, compared to control
(Figure 3A, left and middle panels). This result validates
CBE1 as a binding site of CTCF, and more importantly
demonstrates a strong and specific effect of CBE1-targeting
vectors. Then, we examined the chromatin architecture sur-
rounding CBE1, and designed circularized chromosome
conformation capture (4C-seq) experiments with CBE1 as
a viewpoint (52). This analysis uncovered an interaction of
CBE1 with an upstream CBE (termed here as CBE2) and
the promoter of PREX1 (Figure 3B and Supplementary
Figure S5A). Interaction between CBE1 and CBE2 is in
the expected convergent orientation (31). In CBE1-targeted
cells, we detected a mild reduction in the interaction fre-
quency with CBE2. To confirm the observed interaction
patterns, we included two additional 4C viewpoints; CBE2
(Figure 3B and Supplementary Figure S5B) and thePREX1
promoter (Figure 3B and Supplementary Figure S5D). In
the control condition, CBE2 interacts with another down-
stream CTCF site (termed here CBE3) (Figure 3B and
Supplementary Figure S5C). However, CBE1 knockout in-
duced a strong interaction frequency between CBE2 and
the PREX1 promoter, suggesting that CBE1 is important
to keep the promoter region in a more accessible chromatin
configuration for transcriptional activation by impeding the
interaction between CBE2 and PREX1 promoter and by
favoring interaction between CBE2 and CBE3. Therefore,
we targeted CBE2 using two different sgRNAs and exam-
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ined cell proliferation and interaction profile of each CBE.
Similar to targeting CBE1 and PREX1, targeting CBE2
markedly reduced cell proliferation in MCF-7, but not in
MDA-MB-231 cells (Figure 3C and D). Interestingly, tar-
geting CBE2 triggered an interaction between CBE3 and
CBE1, which are in a non-convergent orientation (65),
while decreasing the interaction frequency between CBE2
and CBE3 (Supplementary Figure S5). The interaction fre-
quency betweenCBE2 andPREX1 promoter was preserved
after targeting CBE2, suggesting that this is CTCF indepen-
dent (Supplementary Figure S5). Thus, our analysis indi-
cates an intricate interplay between several CBEs for main-
taining a chromatin structure in the PREX1 locus that sup-
ports its induction and enhance stimulation of cell prolifer-
ation by ER.
A chromatin conformation structure around PREX1 pro-
moter allows efficient transcriptional activation by ER
As our results demonstrate that CBE1 is required for
PREX1 expression, our next goal was to identify enhancers
whose activity is attenuated upon targeting CBE1. Build-
ing on eRNAs as a quantitative measure of enhancer ac-
tivity (66), we used Global Run-On sequencing (GRO-
seq) (67) to measure changes in nascent transcription in
CBE1-knockout cells compared to control. The dREG (dis-
criminative Regulatory Element detection from GRO-seq
(dREG)) (68) tool detected 25 putative transcriptional reg-
ulatory elements (TREs) in the PREX1 locus. Notably,
the majority of these elements showed reduced transcrip-
tional activity throughout the whole PREX1 locus in CBE-
targeted cells (Figure 4A; Supplementary Figure S6A and
B). Intersection with publicly available ER ChIP-seq data
showed that one of the elements that showed the most
pronounced attenuation of transcription (interval number
24365 (Figure 4A), which resides betweenPREX1 promoter
and CBE2) has a strong ER binding site (named here
EBE24365) (Supplementary Figure S4C), and contains key
marks of a transcriptionally active ER-bound enhancer
(p300 binding and H3K27Ac; Supplementary Figure S6C)
(40). We validated reduced transcriptional activity by mea-
suring the expression level of enhancer-associated RNAs
(eRNAs) in CBE1-targeted and control cells using qRT-
PCR (Figure 4B). This effect was specific, since eRNA levels
of ER-bound enhancer 1830 (40) showed no change after
targeting CBE1 (Figure 4B). Moreover, CRISPR-targeting
of EBE24365 resulted in ∼2-fold reduction in PREX1 ex-
pression (Supplementary Figure S6D and E), and attenu-
ated cell cycle progression of MCF-7 cells, while having a
much smaller impact on the proliferation ofMDA-MB-231
cells (Figure 4C). This indicates that this regulatory element
(transcription interval 24365) is a functional unit linking
ER activity to PREX1 expression. Therefore, this result
also suggests that CBE1 is required for optimal PREX1 ex-
pression at least in part through EBE24365.
Next, we investigated whether chromatin conformation
changes induced by CBE1 are required for optimal activa-
tion of PREX1 transcription by EBE24365. Therefore, we
first checked the recruitment of ER to EBE24365 in the
presence or absence of CBE1 by ChIP-seq analysis. Surpris-
ingly, we found no clear difference in ER binding between
CBE1-knockout cells compared to control (sgRNA1117
and 1118 induced cells, Figure 4D left and middle panel),
suggesting that CBE1 is required for transcriptional activ-
ity rather than ER binding. As a positive control, we di-
rectly targeted EBE24365 and obtained the expected signif-
icant reduction in ER binding and specific inhibition of
MCF-7 cell proliferation (Figure 4D, right panel, and C).
Additionally, targeting CBE2 did not affect ER binding
to EBE24365 (Supplementary Figure S7B). Altogether, our
results indicate that CTCF binding to its cognate elements
establishes a chromatin conformation structure around the
PREX1 promoter that allows efficient transcriptional acti-
vation by ER (Figure 4E).
PREX1 expression is a bona-fide marker of ER-dependency
and sensitivity to anti-hormonal treatment of breast cancers
At last, we examined whether PREX1 expression can serve
as a biomarker and indicate sensitivity to anti-hormonal
treatment of breast cancer. To explore this, we initially ex-
amined the expression of PREX1 in the METABRIC co-
hort (containing 2000 breast cancer cases (55)), and in the
TCGA dataset (1095 breast cancer samples). This anal-
ysis demonstrated a positive correlation between PREX1
and ESR1 in both datasets (Figure 5A and B). Second,
we interrogated DRIVE (56) and Achilles (57) datasets
and found out that PREX1 expression levels are associated
with ER-dependency in breast cancer cell lines (Figure
5C). At last, we examined the correlation between PREX1
and disease-free survival of breast cancer patients in the
METABRIC dataset. This analysis revealed that PREX1
expression correlates significantly with disease-free survival
of ER-positive breast cancer patients, with low PREX1
levels indicating poor prognosis. (Figure 5D). Moreover,
higher levels of PREX1 were associated with better out-
come only in endocrine therapy treated cases, and not for
patients who did not receive any adjuvant endocrine ther-
apeutics (Figure 5E and F), indicating that PREX1 could
be a predictive biomarker for the efficacy of adjuvant en-
docrine therapy response.
DISCUSSION
In summary, we present here an approach to uncover and
characterize the functional role of genetic elements impor-
tant for chromatin structure in human breast cancer cells.
We focused on ER signaling, being the key-driver in the
majority of breast cancers (69,70) and because ERmainly
binds to distal transcriptional enhancers whose activity is
likely to be dependent on local chromatin conformation
for proper activation of its target genes (15,71). Although
genome-wide chromatin conformation capture (Hi-C) (72)
and ChIA-PET (4) data support the chromatin interactions
mediated by ER, causal evidence for it is lacking. There-
fore, we aimed to target CTCF binding sites in the vicinity
of ER-bound enhancers by using a CRISPR-Cas9-based
screening approach. This allowed us to identify four func-
tional CBEs, each of which is required for local transcrip-
tional activity, suggesting that one or more genes in proxim-
ity of the target sites can be vital for ER function. Though
our study was limited to two cell lines, it demonstrates the
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robustness of functional genetic screens in uncovering the
functional chromatin structure elements in ER pathway.
Our results pinpoint a key role of CBEs in mediating
chromatin interactions that established robust expression
of PREX1 by ER. PREX1 is located at chr20q.13 which
is amplified in 8–29% of breast tumors (63). While ele-
vated PREX1 expression levels are observed in luminal type
breast cancer cell lines and tumors, basal type cancer cell
and tumors, as well as normal breast tissue, have either
lower or no PREX1 expression at all (63). PREX1 func-
tions as a Rac1 activator in cancer cells and downregula-
tion of PREX1 levels repressed breast cancer cell prolifer-
ation and tumorigenesis (63). It has also been documented
that PREX1 levels are inversely correlated with PI3K acti-
vation, and positively correlatedwith ER expression in hu-
man breast tumors (73). Here, we validated the expression
correlation ofPREX1 and ER, show thatPREX1 is highly
expressed in ER−driven breast cancer cell lines, and corre-
lates with patient survival and sensitivity to anti-hormonal
treatment of breast cancer.
Although a link between ER and PREX1was described
before, the exact mechanism how ER regulates PREX1 re-
mained elusive. For example, Barrio-Real et al. have sug-
gested that the methylation status of PREX1 promoter can
determine responsiveness to ER activity (74). Neverthe-
less, our study provides a mechanistic explanation to the
PREX1 and ER link in breast cancer, and proposes a key
role for CTCF and chromatin conformation in the regula-
tion of PREX1 expression in breast cancer.
Since thePREX1 locus is amplified inMCF-7 cells (seven
copies; (75)), loss of genomicDNAby generating two simul-
taneous cuts emerges as a possibility. However, CRISPR-
mediated targeting of CBE1 did not affect neither CTCF
binding to CBE2 nor ER-binding to EBE24365 (Figure 3A
and 4D). Moreover, targeting CBE1 did not change the in-
teraction frequency between CBE2 and CBE3 (Supplemen-
tary Figure S4). In addition, PREX1 locus is also ampli-
fied in MDA-MB-231 cells (four copies; (75)) where we do
not observe any effect on proliferation upon targetingCBE1
(Figure 1D and Supplementary Figure S2B). Therefore, we
conclude that the proliferation effect seen in MCF-7 cells
upon CBE1 targeting is due to the interference with CTCF
binding.
CTCF has a ubiquitous origin in its function. Its con-
tribution to gene expression, heterochromatin spread and
higher-order genomic compartmentalization is still under
investigation. Nora et al. used an auxin-inducible degron
system to elaborate the role of CTCF in gene regulation
and organization of chromatin structure by triggering acute
CTCF degradation (76). Their study revealed the involve-
ment of CTCF in insulation of TADs and in the regulation
of gene expression, while higher-order genomic compart-
mentalization seemed like a CTCF-independent event. Fo-
cusing on CTCF-mediated long-range enhancer-promoter
interactions, Ren et al., used RNAi-mediated CTCF down-
regulation to demonstrate the effect of CTCF on cell type
specific genes (77). Moreover, a CRISPR-mediated deletion
of CTCF at the TFF1 locus clearly supported the notion
that CTCF has a critical role in enhancer–promoter inter-
action of cell type specific genes (77). Our results here sup-
port a critical role of CTCF in ER-mediated regulation
of gene expression by shaping enhancer–promoter interac-
tions in breast cancer cells.
Our results indicate the importance of both CTCF and
ER binding for achieving an optimal transcription ac-
tivation of PREX1. We observed that PREX1 expression
level was attenuated in the absence of estrogen signaling
(Figure 2E), but more severely affected estrogen depriva-
tion was combined with loss of CTCF binding to CBE1.
Moreover, even 6 h of estrogen signaling was not sufficient
to stimulate the PREX1 transcription level in the absence
CTCF-binding to CBE1 (Figure 2E). Therefore, CTCF-
mediated chromatin conformation seems crucial to main-
tain ER-mediated gene expression in the PREX1 locus.
This conclusion is supported by the data obtained by Zhang
et al. who also observed that CTCF binding is required
for ER-mediated transcription of the estrogen responsive
gene TFF1 (78). In their work, ER chromatin binding was
blocked upon CTCF knockdown. Differently, we observed
that while eRNA expression of the most prominent ER-
bound enhancer (EBE24365) in the PREX1 locus was com-
promised, ER-binding to this site was not altered (Figure
4A, B and D). It is known that tightly enclosed chromatin
interactions are required to maintain optimal transcrip-
tional levels by inducing efficient cycling of the transcrip-
tional machinery (4,79,80). Additionally, CTCF interacts
directly with the large subunit of RNAPII (81) to modulate
transcription, allow accurate transcription initiation, and
induce transcription initiation pausing. Thus, ER bind-
ing at the PREX1 locus requires CTCF binding to effec-
tively activate transcription. Whether transcriptional initi-
ation, or elongation, or both is affected by CTCF remains
to be elucidated.
The most prominent structural interaction in the PREX1
locus is observed between CBE2 and CBE3 (see Figure 4E).
An additional interaction with lower frequency is observed
between CBE1 and CBE2. CRISPR-Cas9 mediated muta-
tions at CBE1 stimulated the interaction frequency between
CBE2 and PREX1 promoter, and led to downregulation of
PREX1 transcription (Figure 2A). We therefore speculate
that the increased CBE2- PREX1 promoter interaction fre-
quency following CBE1 targeting is inhibitory to PREX1
transcriptional activity either because of reduced accessibil-
ity of transcription factors to the promoter region, reduced
binding of RNAPII or direct inhibition.
Interestingly, also preventing CTCF binding to CBE2
(Figure 3A) caused a strong downregulation of PREX1 ex-
pression (Supplementary Figure S7A). This effect could not
be explained by changes in ER binding to sites in the re-
gion (Supplementary Figure S7B). In contrast, we did ob-
serve changes in chromatin conformationwhich can explain
the requirement of CTCF binding to CBE2 for PREX1 ex-
pression (Figure 4D). Two interactions are favored as a re-
sult of targeting CBE2: between CBE2 and PREX1 pro-
moter and between CBE3 and CBE1 (Supplementary Fig-
ure S7C).We speculate that both of these interactions are in-
hibitory.While CBE3-CBE1 interactionmay affect progres-
sion of transcription CBE2-PREX1 promoter interaction
may affect initiation leading to a greater effect on PREX1
gene expression than targeting CBE1 or EBE24365.
When we examined T47D, another ER positive breast
cancer cell line; we found that CTCF did not bound CBE1
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in this cell line (Supplementary Figure S8A). In line with
this, when CBE1 was targeted either by sgRNA1117 or
sgRNA118, no change in PREX1 expression was detected
(Supplementary Figure S8B). Also, ER binding pattern
and eRNA activity show differences between MCF-7 and
T47D (Supplementary Figure S8C). Therefore, as noted be-
fore (15), cell type specific patterns of CTCF binding can
shape gene expression changes in response to E2.
Our detailed biochemical analysis of PREX1 locus indi-
cated that a correct chromatin structure is required for tran-
scriptional activity of a nearby key ER-bound enhancer
(as determined by eRNA expression), but it is dispensable
for ER binding. This can be explained by reduced interfer-
ence with promoter activity through a competitive mecha-
nism between an upstream and a downstream CTCF sites.
Recently, a similar mechanism was observed for c-MYC,
where the promoter of PVT1 competes with the promoter
of c-MYC for engagement with nearby enhancer elements,
pinpointingPVT1 promoter as a DNA element with poten-
tial tumor suppressing activity (82). This suggests that com-
petitive chromatin regulatorymechanisms are common and
are employed by cancer cells to stimulate tumor prolifera-
tion.
Altogether, our study shows that the CRISPR-Cas9 tech-
nology is a robust tool to identify and characterize func-
tional regulatory nodes of chromatin conformation in an
unbiased fashion. Furthermore, our study adds more ev-
idence for the importance of CTCF-mediated chromatin
conformation for gene expression and oncogenic signaling.
As our approach here was based on a selected group of
CTCF sites residing in the vicinity of ER-enhancers, it is
possible that some ER-binding sites function to regulate
target gene expression independently of CTCF-mediated
chromatin conformation. To address this issue, a genome
wide CTCF-binding site screen is required. Indeed, it is ex-
pected that the approach we presented here will be scaled up
and be used to uncover novel functions of chromatin regu-
latory elements of the human genome under normal and
pathological conditions. Nevertheless, our study highlights
the importance of chromatin conformation in gene regula-
tion and supports the notion that mutations in these regions
can influence local gene expression and cellular phenotypes
such as cancer progression.
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